OrbiMed Capital GP VII LLC
CIK 1760648 · last filed 2026-09-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KNTE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ETRA | Director | 3,090,244 | — | — | $60.00M | 1 | 2026-09-23 |
| KROS | Director | 45,057 | $11.33 | $510.5K | $18.01M | 2 | 2025-12-18 |
| PASG | 10%+ Owner | 313,980 | $3.36 | $1.05M | $17.76M | 13 | 2025-06-26 |
| MBX | Director | 3,205,930 | $50.29 | $161.23M | $6.06M | 1 | 2025-02-19 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $7.74M | 3 | 2024-02-14 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 36,571 | $28.69 | $1.05M | $52.66M | 2 | 2023-07-17 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 794,368 | $2.65 | $2.11M | $70.72M | 2 | 2023-05-02 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 762,400 | $52.95 | $40.37M | $5.00M | 1 | 2022-12-28 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 226,704 | $54.99 | $12.47M | $0 | 1 | 2022-01-28 |
| JANX | Director | 2,403,566 | $16.69 | $40.12M | -$22.50M | 1 | 2021-12-17 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 97,293 | $2.65 | $257.8K | $40.50M | 3 | 2021-09-02 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 633,100 | $14.59 | $9.24M | $30.00M | 1 | 2021-07-16 |
Recent Filings · Page 4 of 4
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-04-13 | KROS | Mixed | +3,806,202 | $18.01M | EDGAR |
| 2020-03-03 | PASG | Mixed | +11,894,646 | $13.44M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.